Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Al-Sharaa denies he called for 80% of Syrians to return from Germany - 2Most loved Fish Dish: What's Your Sea Pleasure?
- 3South Carolina measles outbreak grows by nearly 100, spreads to North Carolina and Ohio
- 4Figure out How to Protect Your Gold Venture from Unpredictability
- 5NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- Top Pastry: What's Your Sweet Treat of Decision?
- Putin critic gets six years in penal colony, vows hunger strike
- Savvy Watches: Which One Is Appropriate for You?
- New movies to watch this weekend: See 'Wake Up Dead Man: A Knives Out Mystery' in theaters, rent 'Bugonia,' stream 'Caught Stealing' on Netflix
- Trump says Venezuela will start 'turning over' oil to the U.S. Is that the reason he toppled Maduro — or is it something else?
- Israel's Druze use AI to present to UN testimonies of 'sexual terrorism' against Syrian Druze women
- Turning into a Distributed Writer: My Composing Process
- US FDA approves Kura-Kyowa's blood cancer therapy
- OECD: Iran war dampening global growth
